NCT06167915View on ClinicalTrials.gov

Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

December 26, 2024

Study Completion Date

December 31, 2024

Conditions
SARS-CoV-2COVID-19 Vaccine
Interventions
BIOLOGICAL

30μg dose of LYB002V14

30μg dose of LYB002V14 vaccine IM, on day 0

BIOLOGICAL

60μg dose of LYB002V14

60μg dose of LYB002V14 vaccine IM, on day 0

BIOLOGICAL

placebo

placebo IM, on day 0

Trial Locations (1)

Unknown

West China Second University Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

Yantai Patronus Biotech Co., Ltd.

INDUSTRY

lead

Guangzhou Patronus Biotech Co., Ltd.

INDUSTRY